NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report)'s stock price reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $19.12 and last traded at $18.61, with a volume of 711302 shares traded. The stock had previously closed at $18.36.
Analyst Ratings Changes
Several equities research analysts recently commented on the stock. Jefferies Financial Group initiated coverage on shares of NeoGenomics in a research report on Tuesday, December 10th. They issued a "buy" rating and a $22.00 price objective on the stock. Benchmark reaffirmed a "buy" rating and issued a $18.00 price target on shares of NeoGenomics in a report on Tuesday, September 24th. Bank of America raised their price objective on shares of NeoGenomics from $18.00 to $19.00 and gave the stock a "neutral" rating in a research note on Friday, December 13th. Finally, Needham & Company LLC restated a "buy" rating and set a $19.00 price objective on shares of NeoGenomics in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $20.30.
Get Our Latest Stock Report on NeoGenomics
NeoGenomics Price Performance
The company has a market capitalization of $2.39 billion, a price-to-earnings ratio of -30.51 and a beta of 1.24. The company has a fifty day simple moving average of $16.81 and a two-hundred day simple moving average of $15.63. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.91 and a current ratio of 1.99.
NeoGenomics (NASDAQ:NEO - Get Free Report) last released its earnings results on Tuesday, November 5th. The medical research company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.01 by $0.04. The firm had revenue of $167.80 million during the quarter, compared to analyst estimates of $167.00 million. NeoGenomics had a negative return on equity of 2.11% and a negative net margin of 12.07%. The business's quarterly revenue was up 10.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.06) earnings per share. As a group, research analysts anticipate that NeoGenomics, Inc. will post -0.16 earnings per share for the current year.
Insider Buying and Selling
In related news, General Counsel Alicia C. Olivo sold 5,175 shares of the stock in a transaction on Friday, November 15th. The stock was sold at an average price of $15.36, for a total value of $79,488.00. Following the completion of the sale, the general counsel now directly owns 37,129 shares in the company, valued at approximately $570,301.44. This represents a 12.23 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.30% of the company's stock.
Institutional Investors Weigh In On NeoGenomics
A number of large investors have recently modified their holdings of NEO. Versant Capital Management Inc increased its stake in NeoGenomics by 174.9% during the 4th quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company's stock worth $30,000 after buying an additional 1,142 shares during the period. Quarry LP purchased a new stake in shares of NeoGenomics during the third quarter worth about $40,000. Blue Trust Inc. lifted its stake in shares of NeoGenomics by 42.3% in the third quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company's stock worth $46,000 after acquiring an additional 987 shares in the last quarter. Canada Pension Plan Investment Board purchased a new position in NeoGenomics in the second quarter valued at about $57,000. Finally, KBC Group NV grew its stake in NeoGenomics by 33.1% during the 3rd quarter. KBC Group NV now owns 4,530 shares of the medical research company's stock valued at $67,000 after purchasing an additional 1,127 shares in the last quarter. Institutional investors and hedge funds own 98.50% of the company's stock.
NeoGenomics Company Profile
(
Get Free Report)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Featured Articles
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
